EA201690314A1 - Анти-garp-белок и его применения - Google Patents

Анти-garp-белок и его применения

Info

Publication number
EA201690314A1
EA201690314A1 EA201690314A EA201690314A EA201690314A1 EA 201690314 A1 EA201690314 A1 EA 201690314A1 EA 201690314 A EA201690314 A EA 201690314A EA 201690314 A EA201690314 A EA 201690314A EA 201690314 A1 EA201690314 A1 EA 201690314A1
Authority
EA
Eurasian Patent Office
Prior art keywords
garp
protein
applications
tgf
binds
Prior art date
Application number
EA201690314A
Other languages
English (en)
Other versions
EA035550B1 (ru
Inventor
Софи Лукас
Пьерр Кули
Юлиа Куэнде Вилласур
Лор Дюмутье
Жан-Кристоф Рено
Себастиан Ван Де Вонинг
Майкл Сондерс
Ханс Де Хард
Гитте Де Бук
Original Assignee
Юниверсите Католик Де Лувэн
Людвиг Инститьют Фор Кэнсер Рисерч Лтд.
арДЖЕН-ИКС Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP13178958.8A external-priority patent/EP2832747A1/en
Application filed by Юниверсите Католик Де Лувэн, Людвиг Инститьют Фор Кэнсер Рисерч Лтд., арДЖЕН-ИКС Н.В. filed Critical Юниверсите Католик Де Лувэн
Publication of EA201690314A1 publication Critical patent/EA201690314A1/ru
Publication of EA035550B1 publication Critical patent/EA035550B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Настоящее изобретение относится к белку, связывающемуся с GARP в присутствии TGF-β, и к его применениям.
EA201690314A 2013-08-01 2014-08-01 АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С КОМПЛЕКСОМ hGARP/TGF-B1, И ИХ ПРИМЕНЕНИЕ EA035550B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361861008P 2013-08-01 2013-08-01
EP13178958.8A EP2832747A1 (en) 2013-08-01 2013-08-01 Anti-GARP protein and uses thereof
EP14167425 2014-05-07
PCT/EP2014/066650 WO2015015003A1 (en) 2013-08-01 2014-08-01 Anti-garp protein and uses thereof

Publications (2)

Publication Number Publication Date
EA201690314A1 true EA201690314A1 (ru) 2016-07-29
EA035550B1 EA035550B1 (ru) 2020-07-06

Family

ID=52431038

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690314A EA035550B1 (ru) 2013-08-01 2014-08-01 АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С КОМПЛЕКСОМ hGARP/TGF-B1, И ИХ ПРИМЕНЕНИЕ

Country Status (16)

Country Link
US (5) US10000572B2 (ru)
EP (2) EP3027650B1 (ru)
JP (3) JP2016529892A (ru)
KR (2) KR102362609B1 (ru)
CN (2) CN113583128A (ru)
AU (3) AU2014298373B2 (ru)
BR (1) BR112016002199B8 (ru)
CA (1) CA2919765C (ru)
EA (1) EA035550B1 (ru)
ES (1) ES2860952T3 (ru)
IL (2) IL243899B (ru)
MX (2) MX2016001356A (ru)
NZ (1) NZ717476A (ru)
SG (2) SG10201800889SA (ru)
WO (1) WO2015015003A1 (ru)
ZA (1) ZA201601085B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
CN113583128A (zh) * 2013-08-01 2021-11-02 鲁汶大学 抗garp蛋白及其用途
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
JP2018529642A (ja) * 2015-07-22 2018-10-11 ホスピタル サント ジョアン デ デューＨｏｓｐｉｔａｌ Ｓａｎｔ Ｊｏａｎ Ｄｅ Ｄｅｕ Ｃａｓｒを発現する癌（例えば神経芽腫）のための免疫療法
AU2016325858B2 (en) * 2015-09-24 2022-05-26 Daiichi Sankyo Company, Limited Anti-GARP antibody
ES2861449T3 (es) * 2015-12-02 2021-10-06 Stcube & Co Inc Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
ES2951648T3 (es) * 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
EP3436480A4 (en) * 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
BR112019000621A2 (pt) * 2016-07-14 2019-04-24 Scholar Rock, Inc. anticorpos tgfss, métodos e usos
JP2020516276A (ja) * 2017-04-14 2020-06-11 ザ ジェネラル ホスピタル コーポレイション 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3752170A4 (en) * 2018-02-12 2022-03-30 The General Hospital Corporation CHIMERA ANTIGEN RECEPTOR T-CELLS TARGETED AGAINST THE TUMOR MICRO ENVIRONMENT
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
CA3124796A1 (en) 2018-12-24 2020-07-02 Sanofi Multispecific binding proteins with mutant fab domains
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
JPWO2021079958A1 (ru) 2019-10-25 2021-04-29
US11548871B2 (en) 2019-11-15 2023-01-10 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
US20230050148A1 (en) 2020-01-11 2023-02-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
JP2021168619A (ja) 2020-04-16 2021-10-28 デンカ株式会社 アデノウイルスの免疫測定方法及び免疫測定器具
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
CA3198003A1 (en) * 2020-12-02 2022-06-09 Jiin-Tarng WANG Anti-garp/tgf? antibodies and methods of use
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
EP4279509A1 (en) * 2021-01-18 2023-11-22 Shanghai Jemincare Pharmaceuticals Co., Ltd. Garp protein antibody and application thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US20220411405A1 (en) 2021-05-11 2022-12-29 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
JP2024517479A (ja) 2021-05-13 2024-04-22 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2024018046A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
WO2024023797A1 (en) 2022-07-29 2024-02-01 Abbvie Biotherapeutics Inc. ANTI-GARP-TGF-β1/PD-1 COMBINATION THERAPY

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
NZ298145A (en) * 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
CN1333274A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
US8815526B2 (en) 2005-03-31 2014-08-26 Case Western Reserve University Methods and reagents for identifying/isolating T regulatory (Treg) cells and for treating individuals
EP2001509A1 (en) 2006-04-03 2008-12-17 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
CN101808664A (zh) * 2007-08-24 2010-08-18 学校法人庆应义墪 肿瘤细胞所导致的免疫抑制的解除剂及使用该解除剂的抗肿瘤剂
EP2842565B1 (en) * 2007-10-25 2016-08-24 The Scripps Research Institute Antibody-mediated disruption of quorum sensing in bacteria
WO2009073163A1 (en) * 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
ES2848323T3 (es) * 2008-01-31 2021-08-06 Inst Nat Sante Rech Med Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8951793B2 (en) 2008-08-21 2015-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of making an isolated population of FOXP3+ regulatory T cells
DK2890711T3 (en) 2012-08-31 2017-02-27 Argen-X Nv Process for Preparation of Inter-species, Intra-Target Cross-Reactivity Antibody Molecules
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
EP2832747A1 (en) 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
CN113583128A (zh) * 2013-08-01 2021-11-02 鲁汶大学 抗garp蛋白及其用途
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
AU2016325858B2 (en) 2015-09-24 2022-05-26 Daiichi Sankyo Company, Limited Anti-GARP antibody
BR112019000621A2 (pt) 2016-07-14 2019-04-24 Scholar Rock, Inc. anticorpos tgfss, métodos e usos

Also Published As

Publication number Publication date
US20200181276A1 (en) 2020-06-11
US20200087404A1 (en) 2020-03-19
IL276106A (en) 2020-08-31
ES2860952T3 (es) 2021-10-05
EA035550B1 (ru) 2020-07-06
BR112016002199B1 (pt) 2023-10-17
MX2016001356A (es) 2016-10-26
EP3786187A1 (en) 2021-03-03
KR102362609B1 (ko) 2022-02-11
CN105658666A (zh) 2016-06-08
US20160251438A1 (en) 2016-09-01
CA2919765C (en) 2023-03-21
SG10201800889SA (en) 2018-03-28
KR20220025174A (ko) 2022-03-03
ZA201601085B (en) 2022-09-28
IL243899A0 (en) 2016-04-21
CN113583128A (zh) 2021-11-02
BR112016002199B8 (pt) 2024-03-05
EP3027650A1 (en) 2016-06-08
WO2015015003A1 (en) 2015-02-05
EP3027650B1 (en) 2021-01-13
KR20160056880A (ko) 2016-05-20
AU2014298373B2 (en) 2019-12-05
US20190016811A1 (en) 2019-01-17
NZ717476A (en) 2022-04-29
MX2019011952A (es) 2019-12-05
SG11201600741SA (en) 2016-02-26
US11230603B2 (en) 2022-01-25
JP2020073504A (ja) 2020-05-14
AU2014298373A1 (en) 2016-02-18
CA2919765A1 (en) 2015-02-05
JP2016529892A (ja) 2016-09-29
CN105658666B (zh) 2021-07-27
BR112016002199A2 (pt) 2017-08-29
US10604579B2 (en) 2020-03-31
AU2021277761A1 (en) 2021-12-23
IL243899B (en) 2020-07-30
JP2022070946A (ja) 2022-05-13
US10822424B2 (en) 2020-11-03
AU2019268046A1 (en) 2019-12-05
US10000572B2 (en) 2018-06-19
US20160272717A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
EA201690314A1 (ru) Анти-garp-белок и его применения
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201892386A1 (ru) Химерные нейротоксины
MX2022008781A (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201691765A1 (ru) Молекулы антител против lag-3 и их применения
EA201691991A1 (ru) Мультиспецифические антитела
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
UA113129C2 (xx) ЗЛИТА КОНСТРУКЦІЯ АНТИТІЛО ПРОТИ CD38 З ОСЛАБЛЕНИМ ІНТЕРФЕРОНОМ АЛЬФА-2b
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
SG10201811017QA (en) Novel antibody frameworks
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM